Display options
Cite
Truedsson M, Malm J, Barbara Sahlin K, et al. Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med. 2016;5(1):9doi: 10.1186/s40169-016-0086-5.
Truedsson, M., Malm, J., Barbara Sahlin, K., Bugge, M., Wieslander, E., Dahlbäck, M., Appelqvist, R., Fehniger, T. E., & Marko-Varga, G. (2016). Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clinical and translational medicine, 5(1), 9. https://doi.org/10.1186/s40169-016-0086-5
Truedsson, Mikael, et al. "Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study." Clinical and translational medicine vol. 5,1 (2016): 9. doi: https://doi.org/10.1186/s40169-016-0086-5
Truedsson M, Malm J, Barbara Sahlin K, Bugge M, Wieslander E, Dahlbäck M, Appelqvist R, Fehniger TE, Marko-Varga G. Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med. 2016 Mar;5(1):9. doi: 10.1186/s40169-016-0086-5. Epub 2016 Mar 07. PMID: 26951192; PMCID: PMC4781824.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Med. 2016 Mar;5(1):9. doi: 10.1186/s40169-016-0086-5. Epub 2016 Mar 07.

Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study.

Clinical and translational medicine

Mikael Truedsson, Johan Malm, K Barbara Sahlin, May Bugge, Elisabet Wieslander, Magnus Dahlbäck, Roger Appelqvist, Thomas E Fehniger, György Marko-Varga

Affiliations

  1. Örestadskliniken, Eddagatan 4, 217 67, Malmö, Sweden. [email protected].
  2. Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02, Malmö, Sweden. [email protected].
  3. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  4. Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02, Malmö, Sweden. [email protected].
  5. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  6. Örestadskliniken, Eddagatan 4, 217 67, Malmö, Sweden. [email protected].
  7. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  8. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  9. Clinical Protein Science and Imaging, Biomedical Centre, Department of Biomedical Engineering, BMC D13, Lund University, 221 84, Lund, Sweden. [email protected].
  10. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  11. Clinical Protein Science and Imaging, Biomedical Centre, Department of Biomedical Engineering, BMC D13, Lund University, 221 84, Lund, Sweden. [email protected].
  12. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden.
  13. Clinical Protein Science and Imaging, Biomedical Centre, Department of Biomedical Engineering, BMC D13, Lund University, 221 84, Lund, Sweden.
  14. Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84, Lund, Sweden. [email protected].
  15. Clinical Protein Science and Imaging, Biomedical Centre, Department of Biomedical Engineering, BMC D13, Lund University, 221 84, Lund, Sweden. [email protected].
  16. First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjiku, Shinjiku-ku, Tokyo, 160-0023, Japan. [email protected].

PMID: 26951192 PMCID: PMC4781824 DOI: 10.1186/s40169-016-0086-5

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is an irreversible disease, diagnosed predominantly in smokers. COPD is currently the third leading cause of death worldwide. Far more than 15 % of smokers get COPD: in fact, most develop some amount of pulmonary impairment. Smoking-related COPD is associated with both acute exacerbations and is closely correlated to comorbidities, such as cardiovascular disease and lung cancer. The objective of our study (KOL-Örestad) is to identify biomarkers in smokers and ex-smokers, with early signs of COPD, and compare these biomarkers with those of non-smokers and healthy smokers/ex-smokers. The participants in the study are recruited from Örestadskliniken, a primary health care clinic in Malmö, Sweden.

METHODS: Two hundred smokers and ex-smokers diagnosed with COPD with airflow restriction according to GOLD stages 1-4 will be included and compared with 50 healthy never-smokers, and 50 healthy smokers/ex-smokers without airflow restriction (total n = 300). The age distribution is 35-80 years. The participants undergo a health examination including medical history, smoking history, lung function measurements, and respond to a "Quality of Life" questionnaire. Blood samples are drawn every 6 months during a period of 5 years. Additional blood sample collection is performed if participants are experiencing an exacerbation. The blood fractions will be analyzed by standard clinical chemistry assays and by proteomics utilizing mass spectrometry platforms. Optimal sample integrity is ensured by rapid handling with robotic biobank processing followed by storage at -80 °C. The study has been approved by the Regional Ethical Review Board in Lund ( http://epn.se/en ), (Approval number: DNR 2013/480), and registered at the NIH clinical trial registry ( http://clinicaltrials.gov ).

RESULTS AND DISCUSSION: Currently, 220 subjects are enrolled in the study.

CONCLUSIONS AND FUTURE DIRECTIONS: The study design will enable discovery of new biomarkers by using novel mass spectrometric techniques that define early changes of COPD. Such panels of novel biomarkers may be able to distinguish COPD from closely related diseases, co-morbidities, and contribute to an increased understanding of these diseases. Graphical abstract KOL-Örestad Study.

Keywords: Biobanking; Biomarkers; COPD; Clinical study; Proteomics

References

  1. BMJ Open. 2013 Feb 01;3(2):null - PubMed
  2. J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
  3. J Proteome Res. 2014 Dec 5;13(12):5310-8 - PubMed
  4. J Proteome Res. 2013 Jul 5;12(7):3087-92 - PubMed
  5. Clin Cancer Res. 2010 Jul 1;16(13):3299-318 - PubMed
  6. J Proteome Res. 2011 Mar 4;10(3):1151-9 - PubMed
  7. Am J Respir Crit Care Med. 2012 Nov 15;186(10):982-8 - PubMed
  8. Radiology. 2011 Oct;261(1):274-82 - PubMed
  9. Mol Oncol. 2008 Oct;2(3):213-22 - PubMed
  10. Proteomics. 2008 Aug;8(15):3030-41 - PubMed
  11. J Proteomics. 2013 Dec 16;95:38-45 - PubMed
  12. Lancet. 2015 May 2;385(9979):1778-88 - PubMed
  13. Lancet. 2006 Apr 15;367(9518):1216-9 - PubMed
  14. Radiology. 2015 Oct;277(1):192-205 - PubMed
  15. Lancet Respir Med. 2013 Mar;1(1):73-83 - PubMed
  16. J Thorac Dis. 2014 Nov;6(11):1532-47 - PubMed
  17. Respir Res. 2010 Sep 10;11:122 - PubMed
  18. Thorax. 2014 Jul;69(7):666-72 - PubMed
  19. COPD. 2014 Apr;11(2):177-89 - PubMed
  20. Respir Res. 2011 Nov 04;12:146 - PubMed
  21. Clin Transl Med. 2015 Dec;4(1):67 - PubMed
  22. COPD. 2010 Feb;7(1):32-43 - PubMed

Publication Types